Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.67 HKD | -0.81% | -2.13% | -30.23% |
Mar. 21 | Sisram Medical’s Profit Down in Fiscal 2023 | MT |
Mar. 20 | Sisram Medical Ltd Announces Ordinary Final Cash Dividend for the Year Ended December 31, 2023 | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- The company appears to be poorly valued given its net asset value.
- This company will be of major interest to investors in search of a high dividend stock.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-30.23% | 222M | - | ||
-1.59% | 836M | B+ | ||
-32.14% | 79.27M | - | - | |
+20.10% | 64.64M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 1696 Stock
- Ratings Sisram Medical Ltd